


Original Review Article

# A Study of Pathogenesis and Prevention of Seroma Formation after Mastectomy in Tertiary Care Centre

Abraham Jebakumar R, Sathish Kumar D\*

Associate Professor, Affiliated to MGR Medical University, Tamil Nadu, India

\*Corresponding author email: [sathishkumarsk007@gmail.com](mailto:sathishkumarsk007@gmail.com)

	International Archives of Integrated Medicine, Vol. 6, Issue 8, August, 2019. Copy right © 2019, IAIM, All Rights Reserved. Available online at <a href="http://iaimjournal.com/">http://iaimjournal.com/</a> ISSN: 2394-0026 (P)                      ISSN: 2394-0034 (O)
	Received on: 10-07-2019                      Accepted on: 21-07-2019 Source of support: Nil                      Conflict of interest: None declared.
<b>How to cite this article:</b> Abraham Jebakumar R, Sathish Kumar D. A Study of Pathogenesis and Prevention of Seroma Formation after Mastectomy in Tertiary Care Centre. IAIM, 2019; 6(8): 117-124.	

## Abstract

Post mastectomy seroma remains an unresolved quandary as the risk factors for its formation have still not been identified. Seromas of the axillary space following breast surgery can lead to significant morbidity and delay in the initiation of adjuvant therapy. Various techniques and their modifications have been practiced and published in English literature, but there seems to be no consensus. In this article, all aspects of seroma formation from pathogenesis to prevention including drug therapies have been discussed.

## Key words

Breast, Cancer, Surgery, Drains, Octreotide, Morbidity.

## Introduction

Seroma is a collection of serous fluid in the dead space of post-mastectomy skin flap, axilla or breast following modified radical mastectomy (MRM) or breast conserving surgery (BCS) and is the commonest early sequel [1]. However, there is inconsistency in the definition of seroma across published works. This presumed complication, albeit usually of minor consequence, may prolong recovery, length of

hospital stay and over stretch health budget. The reported incidence of seroma formation varies widely between 15 and 18% [2]. There are several factors implicated in seroma formation like the extent of lymph node clearance, number of positive nodes, the use of postoperative radiation and whether intraoperative lymphatic channel ligation was done or not, but opinion differs as to their individual role in its pathogenesis [2, 3]. The main pathophysiology

of seroma is still poorly understood and remains controversial. The optimal ways to reduce the incidence of seroma formation are unknown.

### **Pathogenesis**

The pathogenesis of seroma has not been fully elucidated. Seroma is formed by acute inflammatory exudates in response to surgical trauma and acute phase of wound healing [4]. Oertli, et al. [5] believed that the fibrinolytic activity contribute to seroma formation. Petrek, et al. [6] in a prospective randomized trial showed that the most significant influencing factors in the causation of seroma were the number and extent of axillary lymph node involvement. However, Gonzalez, et al. [7] and Hashemi, et al. [8] reported that the only statistically significant factor influencing the incidence of seroma formation was the type of surgery. They reported higher seroma rate in MRM than following wide local excision and axillary dissection (BCS). Factors such as age of the patient, obesity, tumor size and neoadjuvant therapy did not influence the incidence of seroma formation in the three mentioned studies. Extensive dissection in mastectomy and axillary lymphadenectomy damages several blood vessels and lymphatics and the subsequent oozing of blood and lymphatic fluid from a large surface area when compared with breast conserving surgery leads to seroma [9]. Seroma accumulation elevates the flaps from the chest wall and axilla there by hampering their adherence to the tissue bed. It thus can lead to significant morbidity such as wound hematoma, delayed wound healing, wound infection, wound dehiscence, prolonged hospitalization, delayed recovery and initiation of adjuvant therapy [4].

### **Prevention and Reduction of Seroma Formation**

There are several techniques in practice that have been reported to prevent or reduce seroma formation, but no single method has been shown to be consistently and reliably effective. They can be discussed as (1) surgical techniques, (2) the use of sealants and sclerotherapy, (3) compression dressing, (4) the use of drains, (5)

shoulder exercise (delayed vs early) and (6) the role of Octreotide.

### **Surgical Techniques**

It is believed that meticulous attention applied to techniques of breast surgery to minimize the leakage from dissected blood vessels and lymphatics and to obliterate the dead space may reduce the incidence of seroma formation [10]. There are several surgical techniques that have been used with this respect, but there are conflicting results in their effectiveness at reducing the incidence and volume of seroma.

### **Tissue Dissection Techniques**

Tissue dissection techniques in breast cancer surgery have been implicated as a major factor that influences the incidence and volume of seroma formation. As Kakos and James [11] in the 1970s suggested the use of electrocautery for breast dissection, it has been shown to decrease incision time, reduce blood loss and transfusion requirements but may be associated with increased wound complications. Ultrasonic dissection is well known in hepatic and cardiovascular surgeries and may create less thermal injuries than electrocautery. Kontos, et al. [12] reported low incidence of seroma accumulation in patients where harmonic scalpel was used. Galatius, et al. [13] showed that the time to removal of drain was significantly lower in the ultrasonic dissection group as a result of reduction in the total amount of drainage after axillary dissection. Wyman and Rogers [14] reported reduced blood loss using laser scalpel for MRM but has no other overall advantage over the conventional surgical technique for mastectomy. Argon enhanced electrosurgery has been shown to reduce intraoperative blood loss and postoperative transfusion requirements. Ridings, et al. [15] did show that argon enhanced electrosurgery also decreased the incidence of seroma formation, whereas Kerin, et al. [16] failed to show the difference in postoperative seroma drainage between argon enhanced electrosurgery and conventional diathermy. Therefore, there seems to be evidence against the use of electrocautery in breast surgery because of

the degree of thermal trauma and inflammation followed by increase in the incidence of seroma formation. This fact is again supported by a study by Porter, et al. [17] which concluded that the use of electrocautery to create skin flaps in mastectomy reduced blood loss but increased the rate of seroma formation. There are inconsistent and inconclusive results on the beneficial role of alternative dissection techniques using ultrasonic scissors and laser scalpel over electrocautery or sharp dissections. These in addition have obvious cost implications.

### **Wound Closure to Reduce or Obliterate Dead Space**

Surgical techniques to reduce or obliterate the dead space following breast surgery and axillary dissection have been shown to reduce the incidence of seroma formation. Historically, Halstead suggested obliteration of the dead space particularly in the axilla to facilitate wound healing [17]. More recently, Chilson, et al. [18] reported a significant decrease in the incidence of post mastectomy seromas ( $p=0.038$ ) and the number of postoperative clinic visits for aspiration of seroma ( $p=0.0001$ ) when flap tacking was carried out. Coveney, et al. [19] showed significantly less drainage in the group of patients where skin flaps were sutured down to the chest wall muscles compared to just conventional skin flap closure. Classe, et al. [20] showed that axillary padding with the use of axillary aponeurosis alternative to closed suction drain after axillary lymphadenectomy with early discharge. They reported 22.2% seroma rate in 207 of their patients. Published reports did not address the additional operating time and cosmetic implications in this surgery, where cosmesis is one of the important considerations. Various authors have reported different techniques with claimed similar efficacy, but it is difficult to draw any conclusion as the studies are non-randomized, vary in closure techniques and some have additional procedures.

### **The Use of Sealants and Sclerotherapy**

Fibrin glue and other sealant agents have been shown in murine experimental models to reduce

seroma formation after mastectomy [21]. However, there are conflicting results on the effect of fibrin glue in reducing seroma formation after breast surgery and axillary lymphadenectomy. Sanders, et al. [22] noted that excessive concentration of fibrinogen in fibrin glue may be counterproductive as it may adversely affect wound healing, but in clinical practice it significantly reduces the overall seroma formation, earlier drain removal and reduced length of hospital stay. Other investigators, however, have refuted this effect and reported that neither fibrin sealants for bovine thrombin have any significant effect on reduction of seroma formation and daily drainage [23, 24]. Jain, et al. [25] opined in their study that usage of drain after application of fibrin sealant probably led to instability of clot formation and thereby non-significant advantage of fibrin sealant in other studies. However, Cipolla, et al. [26] concluded that the higher cost of fibrin glue, cumbersome technique involved in its application and higher aspirate volume indicated that it has no advantage over the use of routine drain after breast surgery. The other sclerosant used to obliterate dead space following was tetracycline. The first study of tetracycline sclerotherapy in the prevention of seroma formation after mastectomy was by Sitzmann, et al. [27] and they reported a significant reduction in the volume of seroma within 48 hours of its application in all five patients. The same effectiveness of tetracycline in reducing seroma formation was shown by Nichter, et al. [28]. However, other authors reported from randomized clinical trials that tetracycline sclerotherapy had no effect at reducing seroma formation and was associated with severe postoperative pain compared with the control group [29, 30]. The efficacy of fibrin glue and other sealants in reduction of the incidence of seroma over simple closure with or without drain, therefore is yet to be proved. The use of sclerotherapy has been abandoned and has no role in seroma reduction.

### **Compression Dressing**

External compression dressing to the chest wall and axilla to obliterate the dead space has been traditionally used to reduce the incidence of seroma formation. Compression dressing generally has been abandoned, as there is only anecdotal evidence in support of its use after surgery for breast cancer. O’Hea, et al. [31] in their randomized trial found that compression dressing failed to reduce the seroma formation and instead increased its incidence. Besides conflicting efficacy the other problems with compression dressing are discomfort and low tolerance by the patients.

### **The Use of Drains**

The use of drains after surgery for breast cancer is probably the most investigated and at the same time most controversial of all the techniques aimed at preventing or reducing the incidence of seroma formation. A drain is used routinely after breast cancer surgery with the understanding that it will reduce or prevent seroma accumulation. Suction drainage was introduced in 1947 by Murphy with the expectation that it will apply negative pressure and obliterate the dead space after excision of breast tissue and axillary dissection [32]. The influence of negative pressure causing skin flap opposition to the chest wall may facilitate wound healing reduce the incidence of wound infection, wound dehiscence or flap necrosis and prevent seroma formation [33]. There are however, controversies correlating to the optimal suction pressure, number of drains, duration of drainage or in fact whether the drain should be used at all following breast cancer surgery [34].

### **Drain Versus No Drain**

Drain continues to be used after breast excisions and axillary dissection in spite of the fact that there is no clear evidence that it totally reduces the incidence of seroma formation. There are authors who do not insert drain after breast cancer surgery because of the belief that it does not prevent seroma formation and is associated with increased wound complications, patient’s discomfort and prolongs hospital care [35, 36]. Talbot and Magarey [37] grouped 90 consecutive

patients who had axillary dissection for breast cancer into those with prolonged drainage, short drainage and no drain and reported the difference in the complication rates or the duration of fluid accumulation in these three groups. Patients with no drain inserted required more frequent aspiration. They concluded that early drain removal or avoidance of drain following axillary lymphadenectomy facilitates early discharge but have no effect on either wound complications or the duration of axillary accumulation. Zavotsky, et al. [38] showed significant extra visits for aspiration of seroma ( $p=0.002$ ) in the undrained group and significantly increased incidence of pain in the drained group ( $p=0.0062$ ).

### **Suction Versus Passive Drainage**

Suction drain is recognized to eliminate the dead space left after breast surgery for cancer therapy preventing growth of seroma [36]. However, the incidence of seroma development has been established to be higher when suction drains were used compared with passive drains, whereas some other investigators reported no significant difference correlating to the rate of seroma between the two types of drains [39, 40]. In contrast, the incidence of seroma was unacceptably high when suction drain was not used in a study by Kopelman, et al. [41].

### **Single Versus Multiple Drains**

Many surgeons usually use more than one drain after mastectomy and axillary dissection and at least two: one at the axilla and the other at the chest wall. Terrell and Singer [42] reported that the use of two drains (axilla and chest wall) is not superior to that of one drain in the axilla in preventing seroma formation in their 84 inpatients. Petrek, et al. [43] randomized 65 patients undergoing axillary dissection or MRM for stage I (or) II carcinoma into one or four suction drains into the axilla. Both groups had a drain in their chest wall dead space. The use of multiple drains in the axilla conferred no advantage as they did not affect the amount and duration of drainage compared with single drain. They therefore recommended the use of a single drain to the axilla after lymphadenectomy.

### **Length of Drainage (Early Vs Late)**

The reported post-operative hospital stay following breast cancer surgery in the UK about a decade ago was 5 to 7 days [44]. Most surgeons tend to remove the drain when the drainage volume was less than 20–50 ml and this may take up to 10 days but increasingly in practice, patients are discharged early with the drain in situ. Kopelman, et al. [41] recommended that drain may be removed if the drainage volume within the first three postoperative days is less than 250 ml, as keeping them longer in situ did not protect against seroma formation. Gupta, et al. [33] in a prospective randomized study grouped patients into 5-day and 8-day drainages after MRM and showed that removal of drain on the fifth post-operative day was safe but was associated with an increase in incidence of seroma aspiration and volume. Dalberg, et al. [45] in a large multicentre Swedish randomized trial showed that early removal of drain shortened the hospital stay without risking high incidence of seroma formation and other wound complication. However, in cases when there is persistent seroma production, increasingly in practice, drains are left in situ to be managed in the community.

### **Shoulder Exercise (Delayed Vs Early)**

Several authors have implicated the role of early shoulder exercise in the pathogenesis of seroma formation after breast cancer surgery and strategies aimed at reduction of seroma formation included delaying postoperative shoulder exercise with added benefit of improved wound healing. Early active postoperative ipsilateral arm movement has been shown to increase seroma formation, whereas delayed shoulder exercise reduce the incidence of seroma without adversely affecting long term shoulder function [46]. In a recent systematic review of delayed versus immediate postoperative exercise following surgery for breast cancer, Shamley, et al. [47] showed that current evidence from 12 randomized controlled trials supports the use of delayed arm exercise programme ( $p=0.00001$ ) to reduce seroma formation. Delayed controlled shoulder exercise programme is superior to

immediate postoperative movement at reducing seroma and there is no evidence that this affects long term shoulder function.

### **The Role of Octreotide**

Octreotide is a long acting somatostatin analogue which suppresses secretion and its role is well documented in reduction of gastrointestinal tract secretions by reduction of splanchnic blood flow. It has also been used to control lymphorrhoea resulting from thoracic duct injury, chylous ascites and after radical neck dissection [48]. It has been shown in animal models to reduce local inflammatory reaction, which is one of the pathophysiological mechanisms implicated in seroma formation and probably can have a direct effect on the lymphatic circulation by reduction of lymph production. Carcoforo, et al. [49] in a prospective trial randomized 261 consecutive patients following axillary dissection for breast cancer into treatment group who received 0.1mg octreotide subcutaneously thrice a day for 5 days starting on the first postoperative day and the control group who received no treatment. In the control group, the mean volume of seroma was  $94.6 \pm 19$  mL/day and the average duration was  $16.7 \pm 3.0$  days, where as in the treatment group, the mean volume of seroma was  $65.4 \pm 21.1$  ml/day ( $p < 0.0001$ ) and the average duration was  $7.1 \pm 2.9$  days ( $p < 0.0001$ ). They found no significant difference in the wound infection and hematoma rates between the two groups and concluded that octreotide may be used successfully for the treatment of seroma following axillary dissection and potentially in its prevention.

### **Conclusion**

It appears that seroma formation after breast cancer surgery is a persistent problem much to the annoyance of surgeon and patient alike, in spite of advances in surgical techniques and hemostasis. Present evidence clearly attributes increase in the incidence of postoperative seroma to electrocautery because of increased thermal trauma. However, reduction of preoperative blood loss makes electrocautery indispensable

because alternatives such as ultrasonic and laser dissection have cost implications. As the exposure of raw area to a relatively less pressurized dead space appears to be yet another pathophysiological factor besides thermal trauma, techniques obliteration of dead space, therefore seem to be advantageous. Various methods thus can be used to obliterate this dead space including tacking of the flaps of mastectomy to the chest wall or the use of surrounding soft tissue to fill in after conserving surgery. Use of sealants appears promising but yet to be unequivocally proved, whereas compression dressing has been largely abandoned. The use of drains to evacuate collection in the dead space is probably the most controversial. Evidence has shown that short term use of drainage system prevents seroma or at least reduces its incidence compared with no drainage. Closed suction drain is preferred and provides better flap apposition to the chestwall and promotes healing. However, low suction drain cause less seroma volume, less duration of seroma flow, earlier drain removal and shorter length of hospital stay. Possible usage of drain and subsequent duration of drainage and suction pressure therefore, remains largely to the clinician's discretion.

## References

1. Kumar S, Lal B, Misra MC. Post-mastectomy seroma: a new look into the aetiology of an old problem. *J R Coll Surg Edinb.*, 1995; 40: 292–294.
2. Akinci M, Cetin B, Aslan S, Kulacoglu H. Factors affecting seroma formation after mastectomy with full axillary dissection. *Acta Chir Belg.*, 2009; 109: 481–483.
3. Kuroi K, Shimosuma K, Taguchi T, et al. Evidence-based risk factors for seroma formation in breast surgery. *Jpn J Clin Oncol.*, 2006; 36: 197–206.
4. Pogson CJ, Adwani A, Ebbs SR. Seroma following breast cancer surgery. *Eur J Surg Oncol.*, 2003; 29: 711–717.
5. Oertli D. Axillary lymphadenectomy. *Chirurg.*, 2000; 78: 196–202.
6. Petrek JA, Peters MM, Nori S, Knauer C, Kinne DW, Rogatko A. Axillary lymphadenectomy. A prospective randomized trial of 13 factors influencing drainage including early or delayed arm mobilization. *Arch Surg.*, 1990; 125: 378–382.
7. Gonzalez EA, Saltzstein EC, Riedner CS, Nelson BK. Seroma formation following breast cancer surgery. *Breast J.*, 2003; 9: 385–388.
8. Hashemi E, Kaviani A, Najafi M, Ebrahimi M, Hooshmand H, Montazeri A. Seroma formation after surgery for breast cancer. *World J Surg Oncol.*, 2004; 2: 44.
9. Loo WT, Chow LW. Factors predicting seroma formation after mastectomy for Chinese breast cancer patients. *Indian J Cancer*, 2007; 44: 99–103.
10. Gong Y, Xu J, Shao J, et al. Prevention of seroma formation after mastectomy and axillary dissection by lymph vessel ligation and dead space closure: a randomized trial. *Am J Surg.*, 2010; 200(3): 352-6.
11. Kakos GS, James AG. The use of cautery in “bloodless” radical mastectomy. *Cancer*, 1970; 666–668.
12. Kontos M, Kothari A, Hamed H. Effect of harmonic scalpel on seroma formation following surgery for breast cancer: a prospective randomized study. *J BUON*, 2008; 13: 223–230.
13. Galatius H, Okholm M, Hoffmann J. Mastectomy using ultrasonic dissection: effect on seroma formation. *Breast*, 2003; 12: 338–341.
14. Wyman A, Rogers K. Randomized trial of laser scalpel for modified radical mastectomy. *Br J Surg.*, 1993; 80: 871–873.
15. Ridings P, Bailey C, Bucknall TE. Argon beam coagulation as an adjunct in breast-conserving surgery. *Ann R Coll Surg Engl.*, 1998; 80: 61–62.

16. Kerin MJ, O'Hanlon DM, Kenny P, Kent PJ, Given HF. Argon-enhanced cutting and coagulation confers advantages over conventional electrocautery for mastectomy. *Eur J Surg Oncol.*, 1996; 22: 571–573.
17. Porter KA, O'Connor S, Rimm E, Lopez M. Electrocautery as a factor in seroma formation following mastectomy. *Am J Surg.*, 1998; 176: 8–11.
18. Chilson TR, Chan FD, Lonser RR, Wu TM, Aitken DR. Seroma prevention after modified radical mastectomy. *Am Surg.*, 1992; 58: 750–754.
19. Coveney EC, O'Dwyer PJ, Geraghty JG, O'Higgins NJ. (1993) Effect of closing dead space on seroma formation after mastectomy – a prospective randomised clinical trial. *Eur J Surg Oncol.*, 1993; 19: 143–146.
20. Classe JM, Dupre PF, François T, Robard S, Theard JL, Dravet F. Axillary padding as an alternative to closed suction drain for ambulatory axillary lymphadenectomy: a prospective cohort of 207 patients with early breast cancer. *Arch Surg.*, 2002; 137: 169–172.
21. Harada RN, Pressler VM, McNamara JJ. Fibrin glue reduces seroma formation in the rat after mastectomy. *Surg Gynecol Obstet.*, 1992; 175: 450–454.
22. El Nakeeb A. Influence of fibrin glue on seroma formation after modified radical mastectomy: a prospective randomized study. *Breast J*, 2009; 15: 671–672.
23. Sanders RP, Goodman NC, Amiss LR Jr, et al. Effect of fibrinogen and thrombin concentrations on mastectomy seroma prevention. *J Surg Res.*, 1996; 61: 65–70.
24. Carless PA, Henry DA. Systematic review and metaanalysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. *Br J Surg.*, 2006; 93: 810–819.
25. Jain PK, Sowdi R, Anderson AD, MacFie J. Randomized clinical trial investigating the use of drains and fibrin sealant following surgery for breast cancer. *Br J Surg.*, 2004; 91: 54–60.
26. Cipolla C, Fricano S, Vieni S et al (2010) Does the use of fibrin glue prevent seroma formation after axillary lymphadenectomy for breast cancer? A prospective randomized trial in 159 patients. *J Surg Oncol.*, 2010; 101: 600–603.
27. Sitzmann JV, Dufresne C, Zuidema GD. The use of sclerotherapy for treatment of postmastectomy wound seromas. *Surgery*, 1983; 11: 233–236.
28. Nichter LS, Morgan RF, Dufresne CR. Rapid management of persistent seromas by sclerotherapy. *Ann Plast Surg.*, 1983; 11: 233–236.
29. Rice DC, Morris SM, Sarr MG, et al. Intraoperative topical tetracycline sclerotherapy following mastectomy: a prospective, randomized trial. *J Surg Oncol.*, 2000; 73: 224–227.
30. McCarthy PM, Martin JK Jr, Wells DC, Welch JS, Ilstrup DM. An aborted, prospective, randomized trial of sclerotherapy for prolonged drainage after mastectomy. *Surg Gynecol Obstet.*, 1984; 162: 418–420.
31. O'Hea BJ, Ho MN, Petrek JA. External compression dressing versus standard dressing after axillary lymphadenectomy. *Am J Surg.*, 1999; 177: 450–453.
32. Mansel RE. How long should suction drains stay in after breast surgery with axillary dissection? *Ann R Coll Surg Engl.*, 1998; 80: 376.
33. Gupta R, Pate K, Varshney S, Goddard J, Royle GT. A comparison of 5-day and 8-day drainage following mastectomy and axillary clearance. *Eur J Surg Oncol.*, 2001; 27: 26–30.
34. Barwell J, Campbell I, Watkins RM, Teasdale C. How long should suction drains stay in after breast surgery with axillary dissection. *Ann R Coll Surg Engl.*, 1997; 79: 435–437.

35. Purushotham AD, McLatchie E, Young D, et al. Randomized clinical trial of no wound drains and early discharge in the treatment of women with breast cancer. *Br J Surg.*, 2002; 89: 286–292.
36. Puttawibul P, Sangthong B, Maipang T, Sampao S, Uttamakul P, Apakupakul N. Mastectomy without drain at pectoral area: a randomized controlled trial. *J Med Assoc Thai.*, 2003; 86: 325–331.
37. Talbot ML, Magarey CJ. Reduced use of drains following axillary lymphadenectomy for breast cancer. *ANZ J Surg.*, 2002; 72: 488–490.
38. Zavotsky J, Jones RC, Brennan MB, Giuliano AE. Evaluation of axillary lymphadenectomy without axillary drainage for patients undergoing breast-conserving therapy. *Ann Surg Oncol.*, 1998; 5: 227–231.
39. Anand R, Skinner R, Dennison G, Pain JA. A prospective randomised trial of two treatments for wound seroma after breast surgery. *Eur J Surg Oncol.*, 2002; 28: 620–622.
40. Bonnema J, Van Geel AN, Lichtenstein DA, Schmitz PIM, Wiggers TA. A prospective randomised trial of high versus low vacuum drainage after axillary dissection for breast cancer. *Am J Surg.*, 1997; 173: 76–79.
41. Kopelman D, Klemm O, Bahous H, Klein R, Krausz M, Hashmonai M. Postoperative suction drainage of the axilla: for how long? Prospective randomised trial. *Eur J Surg.*, 1999; 165:117–120.
42. Terrell GS, Singer JA. Axillary vs combined axillary and pectoral drainage after modified radical mastectomy. *Surg Gynecol Obstet.*, 1992; 175: 437–440.
43. Petrek JA, Peters MM, Cirrincione C, Thaler HT. A prospective randomized trial of single versus multiple drains in the axilla after lymphadenectomy. *Surg Gynecol Obstet.*, 1992; 175: 405–409.
44. Saratzis A, Soumian S, Willetts R, Rastall S, Stonelake PS. Use of multiple drains after mastectomy is associated with more patient discomfort and longer postoperative stay. *Clin Breast Cancer*, 2009; 9: 243–246.
45. Dalberg K, Johansson H, Signomklao T, et al. A randomized study of axillary drainage and pectoral fascia preservation after mastectomy for breast cancer. *Eur J Surg Oncol.*, 2004; 30: 602–609.
46. Lotze MT. Early versus delayed shoulder motion following axillary dissection: a randomised prospective study. *Ann Surg.*, 1981; 193: 288–295.
47. Shamley DR, Barker K, Simonite V, Beardshaw A. Delayed versus immediate exercises following surgery for breast cancer: a systematic review. *Breast Cancer Res Treat.*, 2005; 90: 263–271.
48. Suver DW, Perkins JA, Manning SC. Somatostatin treatment of massive lymphorrhea following excision of a lymphatic malformation. *Int J Pediatr Otorhinolaryngol.*, 2004; 68: 845–850.
49. Carcoforo P, Soliani G, Maestroni U, et al. (2003) Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial. *J Am Coll Surg.*, 2003; 196: 365–369.